Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.66 AUD | +3.94% | +15.79% | +23.36% |
Apr. 17 | Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice | CI |
Apr. 16 | Recce Pharmaceuticals Advances Production of Anti-Infective Medication | MT |
Sales 2024 * | 5.24M 3.39M | Sales 2025 * | 5.7M 3.69M | Capitalization | 135M 87.11M |
---|---|---|---|---|---|
Net income 2024 * | -15M -9.71M | Net income 2025 * | -33M -21.36M | EV / Sales 2024 * | 26.6 x |
Net Debt 2024 * | 4.43M 2.86M | Net Debt 2025 * | 9.31M 6.03M | EV / Sales 2025 * | 25.3 x |
P/E ratio 2024 * |
-8.25
x | P/E ratio 2025 * |
-3.99
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.59% |
1 day | +3.94% | ||
1 week | +15.79% | ||
Current month | +50.00% | ||
1 month | +50.00% | ||
3 months | +24.53% | ||
6 months | +46.67% | ||
Current year | +23.36% |
Managers | Title | Age | Since |
---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 12-04-30 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Thomas Jarrett
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
John Prendergast
CHM | Chairman | 70 | 18-04-23 |
Alan Dunton
BRD | Director/Board Member | 70 | 20-07-13 |
Director/Board Member | - | 17-11-28 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 0.66 | +3.94% | 129,158 |
24-04-29 | 0.635 | -5.22% | 61,589 |
24-04-26 | 0.67 | -2.19% | 136,399 |
24-04-24 | 0.685 | +5.38% | 325,790 |
24-04-23 | 0.65 | +14.04% | 374,631 |
Delayed Quote Australian S.E., April 30, 2024 at 02:10 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+23.36% | 84.95M | |
+34.00% | 664B | |
+29.29% | 567B | |
-7.75% | 354B | |
+18.53% | 330B | |
+4.95% | 286B | |
+13.79% | 234B | |
+4.93% | 199B | |
-9.78% | 196B | |
-4.89% | 148B |
- Stock Market
- Equities
- RCE Stock